Factors that Impact Symptomatic Diabetic Peripheral Neuropathy in Placebo-treated Patients from Two 1-year Clinical Trials Solomon Tesfaye, MD, FRCP 1 , Rup Tandan, MD, FRCP 2 , Edward J. Bastyr III, MD 3,4 , Keri A. Kles, PhD 3 , Vladimir Skljarevski, MD 3 , Karen L. Price, PhD 3 , for the Ruboxistaurin Study Group* 1 Diabetes Research Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom; 2 University of Vermont, College of Medicine, Burlington, Vermont; 3 Lilly Research Laboratories, Indianapolis, Indiana; 4 Indiana University, Indianapolis, Indiana Running title: Symptoms of Diabetic Peripheral Neuropathy Address correspondence to: Professor Solomon Tesfaye Royal Hallamshire Hospital Q Floor, Room 26 Glossop Road Sheffield S102JF UNITED KINGDOM E-Mail: solomon.tesfaye@sth.nhs.uk Disclosure: This study was funded by Eli Lilly & Company Received for publication 27 March 2007 and accepted in revised form 28 June 2007. * See Appendix for complete list of the Ruboxistaurin Study Group. Diabetes Care Publish Ahead of Print, published online July 10, 2007 Copyright American Diabetes Association, Inc., 2007